Does the media refer more to TYRA or XFOR?

In the previous week, Tyra Biosciences had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for Tyra Biosciences and 2 mentions for X4 Pharmaceuticals. Tyra Biosciences' average media sentiment score of 1.07 beat X4 Pharmaceuticals' score of 0.88 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, AAPG or XFOR?

X4 Pharmaceuticals has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 20.05 -$177.71M N/A N/A X4 Pharmaceuticals $35.11M 11.41 -$79.20M -$1.20 N/A

Does the media refer more to XFOR or TRAX?

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for First Tracks Biotherapeutics and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.88 beat First Tracks Biotherapeutics' score of 0.51 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive First Tracks Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INBX or XFOR?

In the previous week, Inhibrx Biosciences had 5 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 7 mentions for Inhibrx Biosciences and 2 mentions for X4 Pharmaceuticals. Inhibrx Biosciences' average media sentiment score of 1.49 beat X4 Pharmaceuticals' score of 0.88 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NVAX or XFOR?

Novavax has higher revenue and earnings than X4 Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $413.80M 4.12 $440.30M -$1.52 N/A X4 Pharmaceuticals $35.11M 11.41 -$79.20M -$1.20 N/A

Is NVAX or XFOR more profitable?

Novavax has a net margin of -59.87% compared to X4 Pharmaceuticals' net margin of -568.80%. Novavax's return on equity of -14.82% beat X4 Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% X4 Pharmaceuticals -568.80% -63.05% -36.89%

Does the media favor NVAX or XFOR?

In the previous week, Novavax had 27 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 29 mentions for Novavax and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.88 beat Novavax's score of 0.21 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 4 Very Positive mention(s) 7 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral X4 Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

X4 Pharmaceuticals (XFOR) Competitors

$4.04 0.00 (0.00%)

As of 04:00 PM Eastern

Compare

XFOR vs. TYRA, AAPG, TRAX, INBX, and NVAX

Should you buy X4 Pharmaceuticals stock or one of its competitors? X4 Pharmaceuticals's main competitors and comparable companies include Tyra Biosciences (TYRA), Ascentage Pharma Group International (AAPG), First Tracks Biotherapeutics (TRAX), Inhibrx Biosciences (INBX), and Novavax (NVAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does X4 Pharmaceuticals compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tyra Biosciences currently has a consensus target price of $48.22, indicating a potential upside of 93.98%. X4 Pharmaceuticals has a consensus target price of $11.25, indicating a potential upside of 178.47%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Tyra Biosciences had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for Tyra Biosciences and 2 mentions for X4 Pharmaceuticals. Tyra Biosciences' average media sentiment score of 1.07 beat X4 Pharmaceuticals' score of 0.88 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. Tyra Biosciences' return on equity of -46.39% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.39%	-43.07%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

X4 Pharmaceuticals has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A
X4 Pharmaceuticals	$35.11M	11.41	-$79.20M	-$1.20	N/A

Tyra Biosciences has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Summary

Tyra Biosciences beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 163.41%. X4 Pharmaceuticals has a consensus price target of $11.25, indicating a potential upside of 178.47%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Ascentage Pharma Group International has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, Ascentage Pharma Group International had 4 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 6 mentions for Ascentage Pharma Group International and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.88 beat Ascentage Pharma Group International's score of 0.49 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. Ascentage Pharma Group International's return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

X4 Pharmaceuticals has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	20.05	-$177.71M	N/A	N/A
X4 Pharmaceuticals	$35.11M	11.41	-$79.20M	-$1.20	N/A

72.0% of X4 Pharmaceuticals shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ascentage Pharma Group International beats X4 Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to First Tracks Biotherapeutics?

X4 Pharmaceuticals (NASDAQ:XFOR) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

First Tracks Biotherapeutics has lower revenue, but higher earnings than X4 Pharmaceuticals. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	11.41	-$79.20M	-$1.20	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

In the previous week, First Tracks Biotherapeutics had 2 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 4 mentions for First Tracks Biotherapeutics and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.88 beat First Tracks Biotherapeutics' score of 0.51 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
First Tracks Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. First Tracks Biotherapeutics' return on equity of 0.00% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%
First Tracks Biotherapeutics	N/A	N/A	N/A

X4 Pharmaceuticals currently has a consensus target price of $11.25, indicating a potential upside of 178.47%. First Tracks Biotherapeutics has a consensus target price of $63.00, indicating a potential upside of 48.20%. Given X4 Pharmaceuticals' higher possible upside, equities research analysts clearly believe X4 Pharmaceuticals is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

X4 Pharmaceuticals beats First Tracks Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 61.54%. X4 Pharmaceuticals has a consensus target price of $11.25, indicating a potential upside of 178.47%. Given X4 Pharmaceuticals' higher probable upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

X4 Pharmaceuticals has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,384.36	-$140.05M	-$8.88	N/A
X4 Pharmaceuticals	$35.11M	11.41	-$79.20M	-$1.20	N/A

Inhibrx Biosciences has a beta of 3.66, suggesting that its share price is 266% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

In the previous week, Inhibrx Biosciences had 5 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 7 mentions for Inhibrx Biosciences and 2 mentions for X4 Pharmaceuticals. Inhibrx Biosciences' average media sentiment score of 1.49 beat X4 Pharmaceuticals' score of 0.88 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -568.80%. X4 Pharmaceuticals' return on equity of -63.05% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

Summary

Inhibrx Biosciences and X4 Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does X4 Pharmaceuticals compare to Novavax?

Novavax (NASDAQ:NVAX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

In the previous week, Novavax had 27 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 29 mentions for Novavax and 2 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 0.88 beat Novavax's score of 0.21 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
X4 Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novavax has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Novavax has a net margin of -59.87% compared to X4 Pharmaceuticals' net margin of -568.80%. Novavax's return on equity of -14.82% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
X4 Pharmaceuticals	-568.80%	-63.05%	-36.89%

Novavax currently has a consensus target price of $14.00, suggesting a potential upside of 35.40%. X4 Pharmaceuticals has a consensus target price of $11.25, suggesting a potential upside of 178.47%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Novavax has higher revenue and earnings than X4 Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$413.80M	4.12	$440.30M	-$1.52	N/A
X4 Pharmaceuticals	$35.11M	11.41	-$79.20M	-$1.20	N/A

53.0% of Novavax shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Novavax beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get X4 Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XFOR vs. The Competition

Export

Metric	X4 Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$400.57M	$4.02B	$7.25B	$12.89B
Dividend Yield	N/A	3.61%	2.53%	8.57%
P/E Ratio	-3.37	12.72	273.59	25.44
Price / Sales	11.41	1,361.39	675.80	124.32
Price / Cash	N/A	105.29	76.98	52.10
Price / Book	2.57	16.29	12.89	6.14
Net Income	-$79.20M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-4.49%	-1.37%	-0.33%	-1.47%
1 Month Performance	-1.22%	11.07%	6.51%	2.47%
1 Year Performance	29.49%	53.71%	25.19%	15.84%

X4 Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XFOR X4 Pharmaceuticals	2.1681 of 5 stars	$4.04 flat	$11.25 +178.5%	+16.4%	$400.57M	$35.11M	N/A	80
TYRA Tyra Biosciences	2.3773 of 5 stars	$26.82 +2.8%	$46.90 +74.9%	+100.6%	$1.60B	N/A	N/A	20	Positive News
AAPG Ascentage Pharma Group International	4.1173 of 5 stars	$16.99 +1.7%	$46.43 +173.2%	-59.8%	$1.59B	$82.10M	N/A	600	Gap Up
TRAX First Tracks Biotherapeutics	3.4367 of 5 stars	$44.25 +2.2%	$63.00 +42.4%	N/A	$1.55B	N/A	N/A	N/A	Analyst Forecast
INBX Inhibrx Biosciences	3.0477 of 5 stars	$107.28 +2.2%	$197.50 +84.1%	+352.5%	$1.54B	$1.30M	N/A	166	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XFOR) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. TYRA, AAPG, TRAX, INBX, and NVAX

How does X4 Pharmaceuticals compare to Tyra Biosciences?

Summary

How does X4 Pharmaceuticals compare to Ascentage Pharma Group International?

Summary

How does X4 Pharmaceuticals compare to First Tracks Biotherapeutics?

Summary

How does X4 Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does X4 Pharmaceuticals compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

X4 Pharmaceuticals (XFOR) Competitors

XFOR vs. TYRA, AAPG, TRAX, INBX, and NVAX

How does X4 Pharmaceuticals compare to Tyra Biosciences?

Do insiders & institutionals have more ownership in TYRA or XFOR?

Do analysts recommend TYRA or XFOR?

Does the media refer more to TYRA or XFOR?

Is TYRA or XFOR more profitable?

Which has better earnings & valuation, TYRA or XFOR?

Which has more risk and volatility, TYRA or XFOR?

Summary

How does X4 Pharmaceuticals compare to Ascentage Pharma Group International?

Do analysts recommend AAPG or XFOR?

Which has more risk & volatility, AAPG or XFOR?

Does the media favor AAPG or XFOR?

Is AAPG or XFOR more profitable?

Which has stronger earnings & valuation, AAPG or XFOR?

Do insiders and institutionals believe in AAPG or XFOR?

Summary

How does X4 Pharmaceuticals compare to First Tracks Biotherapeutics?

Which has better valuation and earnings, XFOR or TRAX?

Does the media refer more to XFOR or TRAX?

Is XFOR or TRAX more profitable?

Do analysts rate XFOR or TRAX?

Do institutionals & insiders believe in XFOR or TRAX?

Summary

How does X4 Pharmaceuticals compare to Inhibrx Biosciences?

Do analysts prefer INBX or XFOR?

Do insiders and institutionals believe in INBX or XFOR?

Which has stronger earnings & valuation, INBX or XFOR?

Which has more risk & volatility, INBX or XFOR?

Does the media refer more to INBX or XFOR?

Is INBX or XFOR more profitable?

Summary

How does X4 Pharmaceuticals compare to Novavax?

Does the media favor NVAX or XFOR?

Which has more volatility and risk, NVAX or XFOR?

Is NVAX or XFOR more profitable?

Do analysts prefer NVAX or XFOR?

Which has preferable earnings and valuation, NVAX or XFOR?

Do insiders and institutionals have more ownership in NVAX or XFOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XFOR vs. The Competition

X4 Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools